Description
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
Cat.No
A647
Name
Concizumab
Chemical Properties
CAS
1312299-39-0
Synonyms
Concizumab;NN 7415;mAb 2021;NNC 0172-0000-2021;Research Grade Concizumab (DHC82802);Research Grade Concizumab (DHC82802);Research Grade Concizumab (DHC82802);Research Grade Concizumab (DHC82802);Research Grade Concizumab (DHC82802);Concizumab (anti-TFPI);Concizumab (anti-TFPI);Concizumab (anti-TFPI);Concizumab (anti-TFPI);mAb 2021|||NN 7415;mAb 2021|||NN 7415;Concizumab (anti-TFPI);mAb 2021|||NN 7415;mAb 2021|||NN 7415;mAb 2021|||NN 7415
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470
Email:
sales@dcchemicals.com
order@dcchemicals.com
Website:
www.dcchemicals.com